Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.
You may also be interested in...
Takeda Discontinues Development Of Cholesterol Compound
News comes after elevated transaminase levels were seen in some patients taking TAK-475 in clinical trials.
Takeda Discontinues Development Of Cholesterol Compound
News comes after elevated transaminase levels were seen in some patients taking TAK-475 in clinical trials.
Actos Franchise Drives Takeda's Pharmaceutical Sales Growth
Firm continues FDA discussions for new cholesterol candidate Tak-475.